Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (111204)"
|Up a level|
- Subjects classification (39565)
- Australian and New Zealand Standard Research Classification (39565)
Group by: Authors/Creators | Item Type
Number of items at this level: 30.
Yates, Patsy (2008) Cancer. In Chang, Esther & Johnson, Amanda (Eds.) Chronic Illness and Disability : Principles for Nursing Practice. Churchill Livingstone Elsevier, Chatswood, NSW, pp. 424-437.
Adamson, R.E., Frazier, A.A., Evans, H., Chambers, Karen F., Schenk, E., Essand, M., et al. (2012) In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus. Human Gene Therapy, 23(2), pp. 218-230.
Bisseling, Karin, Kondalsamy-Chennakesavan, Srinivas, Bekkers, Ruud, Janda, Monika, & Obermair, Andreas (2010) Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynecology, 49(6), pp. 660-666.
Busacca, Sara, Sheaff, Michael, Arthur, Kenneth, Gray, Steven G, O'Byrne, Kenneth J., Richard, Derek J., et al. (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. The Journal of Pathology, 227(2), pp. 200-208.
Byron, Sara A., Loch, David, & Pollock, Pamela M. (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.
Byron, Sara A., Loch, David C., Wellens, Candice L., Wortmann, Andreas, Wu, Jiayi, Wang, John, et al. (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. BMC Molecular Cancer, 11(75).
DiSipio, Tracey, Hayes, Sandi, Newman, Beth M., & Janda, Monika (2008) Health-related quality of life 18 months after breast cancer : comparison with the general population of Queensland, Australia. Supportive Care in Cancer, 16(10), pp. 1141-1150.
Dong, Ying, Batra, Jyotsna, Anand, Kamal, Bapat, Sharmila, & Clements, Judith A. (2014) Transforming the future of treatment for ovarian cancer. Clinical & Experimental Pharmacology, 4(3), p. 1000157.
Galvão, Daniel A., Nosaka, Kazunori, Taafe, Dennis, Peake, Jonathan, Spry, Neil, Suzuki, Katsuhiko, et al. (2008) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer and Prostatic Diseases, 11(2), pp. 160-165.
Gopalan, Vinod, Pillai, Suja, Ebrahimi, Faeza, Salajegheh, Ali, Lam, Tommy C., Le, Tran K., et al. (2014) Regulation of microRNA-1288 in colorectal cancer : altered expression and its clinicopathological significance. Molecular Carcinogenesis, 53(S1), E36-E44.
Graves, Nicholas, Janda, Monika, Merollini, Katharina, Gebski, Val, & Obermair, Andreas (2013) The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. BMJ Open, 3(4).
Gunter, Jennifer H., Lubik, Amy A., McKenzie, Ian, Pollak, Michael, & Nelson, Colleen C. (2012) The interactions between insulin and androgens in progression to castrate resistant prostate cancer. Advances in Urology, 2012, pp. 1-11.
Hollier, Brett G., Evans, KW, & Mani, SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells : a coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia, 14(1), pp. 29-43.
Irani, Soussan, Salajegheh, Ali, Smith, Robert A., & Lam, Alfred King-Yin (2014) A review of the profile of endothelin axis in cancer and its management. Critical Reviews in Oncology/Hematology, 89(2), pp. 314-321.
Janda, Monika, DiSipio, Tracey, Hurst, Cameron P., Cella, David, & Newman, Beth M. (2008) The Queensland cancer risk study: general population norms for the functional assessment of cancer therapy-general (FACT-G). Psycho-Oncology, 18(6), pp. 606-614.
Janda, Monika, Steginga, Suzanne K., Dunn, Jeff, Langbecker, Danette H., Walker, David, & Eakin, Elizabeth G. (2008) Unmet supportive care needs and interest in services among patients with a brain tumour and their carers. Patient Education and Counseling, 71(2), pp. 251-258.
Jeet, Varinder, Russell, Pamela J., Verma, Nirupama D., & Khatri, Aparajita (2012) Targeting aurora kinases : a novel approach to curb the growth and chemoresistance of androgen refractory prostate cancer. Current Cancer Drug Targets, 12(2), pp. 144-163.
Langbecker, Danette H., Janda, Monika, Yates, Patsy, Biggs, Vivien, & Walker, David (2007) Health professionals' perspectives on information delivery for patients newly diagnosed with brain tumours. Asia-Pacific Journal of Clinical Oncology, 3(S2), A49.
Libério, Michelle S., Joanitti, Graziella A., Azevedo, Ricardo B., Cilli, Eduardo M., Zanotta, Lanuse C., Nascimento, Anna C., et al. (2011) Anti-proliferative and cytotoxic activity of pentadactylin isolated from Leptodactylus labyrinthicus on melanoma cells. Amino Acids, 40(1), pp. 51-59.
Ling, Patrick, Luk, Sze U., Al-Ejeh, Fares, & Khanna, Kum K. (2012) Tocotrienol as potential anticancer agent. Carcinogenesis, 33(2), pp. 233-239.
Maitland, Norman, Chambers, Karen F., Georgopoulos, Lindsay, Simpson-Holley, Martha, Leadley, Regina, Evans, Helen, et al. (2010) Gene transfer vectors targeted to human prostate cancer : do we need better preclinical testing systems? Human Gene Therapy, 21(7), pp. 815-827.
Moon, H., Lee, C.S., Inder, K.L., Sharma, S., Choi, E., Black, D.M., et al. (2013) PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene, 33(27), pp. 3561-3570.
Rahman, Md Atiqur, Salajegheh, Ali, Smith, Robert A., & Lam, Alfred King-yin (2014) BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers : development of resistance and future prospects. Current Cancer Drug Targets, 14(2), pp. 128-143.
Rutowski, Raphael, Mertens-Walker, Inga, Lisle, Jessica E, Herington, Adrian C., & Stephenson, Sally-Anne (2012) Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. International Journal of Cancer, 131(5), E614-E624.
Trisilowati,, McCue, Scott W., & Mallet, Daniel G. (2013) Numerical solution of an optimal control model of dendritic cell treatment of a growing tumour. ANZIAM Journal, 54, C664-C680.
Uemura, Hirotsugu, Nelson, Colleen, Schalken, Jack A., & Klotz, Laurence (2012) Personalized cancer therapy for urological cancers: From bench to bedside and back. Advances in Urology, 2012(2012), pp. 1-2.
Wilkinson, Ray, Woods, Katherine, D'Rozario, Rachael, Prue, Rebecca, Vari, Frank, Hardy, Melinda Y, et al. (2012) Human Kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology Immunotherapy, 61(2), pp. 169-179.
de Souza, Paul, Russell, Pamela, Kearsley, John, & Howes, Laurence (2010) Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutrition Reviews, 68(9), pp. 542-555.
Hayes, Sandra C. (2009) Exercise and lymphoedema : Is it good or bad? In The 15th UICC Reach to Recovery International Breast Cancer Support Conference, 13-15 May 2009, Brisbane Convention and Exhibition Centre, Brisbane. (Unpublished)
Langbecker, Danette H., Janda, Monika, Yates, Patsy, Biggs, Vivien, & Walker, David (2008) How can we better meet the information needs of patients newly diagnosed with brain tumours? In International Psycho-Oncology Society 10th World Congress : Advancing Culturally Diverse Approaches in Psycho-Oncology and Palliative Care, 11-13 June 2008, Madrid. (Unpublished)